Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Care management intervention strategies
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Care management intervention strategies

1 evidence topic · 1 source

SCN2A: coordinated epilepsy care

“Individuals with epilepsy/DEE may be followed by a Complex Care Team and/or Case Management.” (opens the source at this quote in a new tab)